News

Primaquine safely and effectively blocks malaria transmission across age-groups and different rates of regional transmission, leading to call for lower, pediatric-appropriate dose formulation.

US outbreaks account for 93% of cases, North Dakota sees first case since 2011, and the Americas Region reports over 2,300 infections.

Jason Barker, ND, details how Vibrant’s platform raises diagnostic sensitivity from 63% to 100%, ensuring more accurate detection and faster treatment for Lyme disease and tick-borne infections.

Sean Nguyen PharmD, BCIDP, medical director Shionogi, delves into the European cohort portion of the study and offers further information from the trial and some of its bigger clinical ramifications.

Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.

The National Foundation for Infectious Diseases (NFID) released its 2025 NFID State of Handwashing Report and found that many US adults forget or choose not to wash their hands at key times when germs can easily spread.

The INSPIRE 3 trial demonstrates that computerized order entry recommendation prompts can reduce empiric use of broad-spectrum antibiotics in favor of targeted treatment for skin and soft tissue infections.

Rising tick-borne illnesses due to warmer winters, strong hepatitis E vaccine efficacy during an outbreak, emerging fungal threats and resistance, and more.

The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.

From the discovery of penicillin to PK-PD principles: A brief historical overview and what we have learned from recent clinical trials.

Despite political restructuring and funding cuts, the NIH’s Generation Gold Standard vaccine platform offers a promising solution for pandemic preparedness and global health resilience.

As the cohort of people living with HIV in the US ages, HIV care programs must rapidly adapt to the changing needs of older adults with HIV.

Andrew Lover, PhD, MPH, discusses the shifting landscape of tick-borne illnesses during Tick-Borne Disease Awareness Month.

Six states hold the highest percentage of A grades.

Jason Barker, ND, explains how standard testing can miss coinfections and how Vibrant’s microarray improves sensitivity and efficiency in a single test.

The Hecolin hepatitis E virus vaccine was delivered with a reduced 2-dose schedule to people living in a refugee camp to try to reduce an outbreak.

Study supports the global need for targeted education to correct misconceptions and improve treatment adherence.

This common skin and soft tissue infection has a high recurrence rate and significant treatment failure. β-Lactams remain effective first-line treatments, though rising resistance to clindamycin and tetracycline, especially in GAS, is a growing concern.

Sabrina Absalon, PhD, explains how antibiotic disruption of the apicoplast led to the discovery of PfAnchor, a key protein required for parasite division and survival.

The agencies are calling for sustained investments in immunization efforts in the midst of increasing case numbers rising for diseases such as whooping cough, measles, and others.

The latest fungal-focused edition of the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases explores the global spread of antifungal resistance, rising cases of Aspergillus infections, and the detection of Histoplasma.

A preclinical study shows the antibiotic, piperacillin, was effective at much lower dosages than doxycycline, and did so without disrupting the gut microbiome.

US cases already surged 210% in 2025, while ECDC reported a 786% increase in Europe, with 35,212 cases in 2024.

Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.

Novavax Vice President Matthew Rousculp on reactogenicity, vaccine hesitancy, and supporting informed decisions.

Matthew Hepburn, MD, offers some insights on his time as vaccine development lead for Operation Warp Speed and the ability to develop a COVID-19 vaccine within a year.

At ESCMID Global 2025, SHIELD study data show Novavax recipients experienced fewer adverse effects and missed less work compared with those who received the Pfizer-BioNTech COVID-19 vaccine.

A recent study evaluated bundled ambulatory stewardship interventions (ASIs) — audits, reporting, webinars, and electronic alerts — to reduce inappropriate antibiotic prescriptions (IAPs) for acute uncomplicated bronchitis (AUB).

World Malaria day stories, update on measles outbreak, coronavirus antivirals showing strong results in testing, and more this week.

After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.